PRTC.LSE PureTech Health plc

Healthcare Life Sciences Tools & Services London Exchange
1.24 GBX
Close of Nov 3, 2026
106.60 143.60
Market cap
GBX 304M
P/E
-
P/B
1.01x
ROE
67.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is PRTC.LSE undervalued?

Graham number

The Graham number of PureTech Health plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PureTech Health plc fundamental analysis

No fundamental analysis for PureTech Health plc yet.

PureTech Health plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PureTech Health plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnano…

Full company profile